

## Sean E. Collins M.D., M.S.

Email: [sean2@stanford.edu](mailto:sean2@stanford.edu)

### Current Position:

---

07/2015- Instructor, Department of Medicine Division of Infectious Diseases, Stanford University  
02/2014- Subinvestigator, Stanford AIDS Clinical Trials Unit, Stanford University School of Medicine

### Education:

---

08/2001 B.S. University of Michigan (Biology with High Distinction)  
05/2008 M.D. Weill Cornell Medical College  
06/2015 M.S. Stanford University (Epidemiology and Clinical Research)

### Post Doctoral Training and Fellowship Appointments:

---

07/2008-06/2011 Internal Medicine Resident, New York-Presbyterian Hospital, New York  
07/2010-06/2011 Assistant Chief Resident, Memorial Sloan-Kettering Cancer Center / New York-Presbyterian Hospital  
07/2011-06/2012 Fogarty International Clinical Research Fellow, Les Centres GHESKIO, Port-au-Prince, Haiti/Center for Global Health, Weill Cornell Medical College, New York  
07/2012-06/2015 Fellow, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine  
08/2013 Intensive Course in Clinical Research, Stanford Center for Clinical and Translational Education and Research  
01/2014-06/2015 Epidemiology and Clinical Research Masters Program, Stanford University School of Medicine: expected graduation June 2015

### Honors and Awards:

---

1999 Phi Beta Kappa, University of Michigan Ann Arbor  
2008 George G. Reader Prize in Public Health, Weill Cornell Medical College  
2008 Jay Lawrence Award for Clinical Infectious Diseases, Weill Cornell Medical College  
2011 A. Lee Winston MD – Ingersoll-Rand Company Award for excellence in clinical care, compassion and humanitarianism. New York-Presbyterian Hospital  
2011 Fogarty International Clinical Research Fellowship, National Institutes of Health  
2013 NIH Training Grant, Fellowship Position: T32 AI052073 Epidemiology of Emerging Infections and Bioterrorism. PI Julie Parsonnet, Stanford  
2014 Young Investigator Scholarship, Conference on Retroviruses and Opportunistic Infections

### Research and Work Experience:

---

03/2008-05/2008 International Research Fellow, Weill Cornell Medical College / Les Centres GHESKIO, Port-au-Prince, Haiti

07/2005-08/2005 International Summer Fellow, Weill Cornell Medical College / ProMujer, Cochabamba, Bolivia,  
08/2003-05/2004 Health Policy Researcher, Colorado State House, Minority Office. Supervisor: Representative Andrew Romanoff  
09/2003-05/2004 Laboratory Technician, Center for Genetic Lung Disease, University of Colorado Health Sciences Center. PI David M. Rodman M.D.  
02/2002-03/2003 Forestry Technician, Peace Corps Morocco, Taforhalt, Oujda.  
03/2000-06/2001 Whitewater Expedition Leader, Drift Nepal Inc. Kathmandu Nepal.  
10/2001-11/2001 Seasonal

### **Publications:**

---

Ocheretina O, Shen L, Escuyer VE, Mabou M-M, Royal-Mardi G, **Collins SE**, et al. Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a “Low-Level” rpoB Mutation L511P – Insights into a Mechanism of Resistance Escalation. **PLoS ONE 2015; 10(6): e0129207**. doi:10.1371/journal.pone.0129207

**Collins SE**, Jean Juste MA, Koenig SP, Secours R, Ocheretina O, Bernard D, Riviere C, Calnan, M, Dunning A, Hurtado Rúa SM, Johnson WD, Pape JW, Fitzgerald DW, Severe P. CD4 Deficit and Tuberculosis Risk Persist with Delayed Antiretroviral Therapy: 5-year Data from CIPRA HT-001. **International Journal of Tuberculosis and Lung Disease 2015; 19(1):50–57**. doi: 10.5588/ijtld.14.0217

Koenig SP, Rouzier V, Vilbrun SC, Morose W, **Collins SE**, Joseph P, Decome D, Ocheretina O, Galbaud S, Hashiguchi L, Pierrot J, Pape JW. Treating Tuberculosis in Haiti in the Aftermath of the 2010 Earthquake. **Bulletin of the World Health Organization 2015; 93:498-502**. doi: 10.2471/BLT.14.145649

**Collins SE**, Grant PM, Richardson ET, Zolopa AR. Integrating Integrase Inhibitors into an Antiviral Regimen. **Current Treatment Options in Infectious Diseases 2014; 6(2):144-158**. doi 10.1007/s40506-013-0009-6.

Ocheretina O, Escuyer VE, Mabou M-M, Royal-Mardi G, **Collins S**, et al. Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results. **PLoS ONE 2014; 9(3): e90569**. doi:10.1371/journal.pone.0090569

Richardson E, **Collins SE**, Kung T, Jones JH, Bekker LG, Zolopa AR. Gender inequality and HIV transmission: A global analysis. **Journal of the International AIDS Society 2014; 17:19035**. doi:10.7448/IAS.17.1.19035

McGreevy J, Jean Juste MA, Severe P, **Collins S**, Koenig S, Pape JW, Fitzgerald DW. Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen. **International Journal of Tuberculosis and Lung Disease 2012, Jun;16(6):841-5**.

Koenig SP, Riviere C, Leger P, Joseph P, Severe P, Parker K, **Collins S**, Lee E, Pape JW, Fitzgerald DW. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. **Clinical Infectious Diseases 2009; Mar 15;48(6):829-31**.

## Manuscripts in Submission

---

**Collins SE**, Grant PM, Shafer RW. Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Review

### Abstracts:

---

**Collins SE**, Jean Juste MA, Severe P, Koenig SP, Secours R, Ocheretina O, Bernard D, Dunning A, Hurtado Rúa SM, Pape JW. Increased Risk of TB and Persistent Immune Deficit with Delayed ART: A Randomized Trial from Haiti. **Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014**, Boston MA, Poster #825.

Richardson E, Loftus J, **Collins S**, Tram K, Kung T, Boggiano V, Zolopa A, Bekker LG, Jones J. Modeling cash incentives vs. oral preexposure prophylaxis in high-risk African women: the Cash-PreP Study. **20<sup>th</sup> International AIDS Conference, July 20-25, 2014**, Melbourne, Australia, Poster LBPE39.

Uwinkindi F, **Collins SE**, Slamowitz D, Seruyange E, Mugeni A, Remera E, Niyonsenga SP, Nyirimigabo J, Uwizihwe JP, Dongier P, Muhayimpundu R, Mazarati J-B, Talbot A, Zolopa A, Grant P, Nsanzimana S. Switch from nevirapine-based regimen to once a day rilpivirine/emtricitabine/tenofovir in virologically-suppressed HIV-infected Rwandans: Week 4 data from the NEAR-Rwanda Randomized Trial. **2014 International Research Conference, December 3-5**, Kigali, Rwanda. Oral presentation (F. Uwinkindi).

Seruyange E, Mugeni A, Uwinkindi F, Muhayimpundu R, Uwizihwe JP, Remera E, Niyonsenga SP, Nyirimigabo J, Dongier P, Mazarati J-B, **Collins S**, Slamowitz D, Grant P, Talbot A, Shafer R, Zolopa R, Nsanzimana S. Implementation of clinical trials in Rwanda: Enrollment experience from “Switch from Nevirapine-based regimen to once a day rilpivirine/emtricitabine/tenofovir in virologically-suppressed HIV-infected Rwandans (“Near-Rwanda”)”. **2014 International Research Conference, December 3-5**, Kigali, Rwanda. Poster presentation.

### Active Research Studies:

---

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir (Near- Rwanda). ClinicalTrials.gov NCT02104700

Simplifying Hepatitis C Antiviral therapy in Rwanda for Elsewhere in the Developing world (SHARED)

**Role:** Co-investigator

Darunavir/cobicistat and dolutegravir to maintain virologic suppression and reduce NRTI-associated toxicity (The 'deNUC' Study; TMC114HIV2030)

**Role:** Protocol Director

Gilead 337-0115: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection. ClinicalTrials.gov NCT02073656

Gilead 292-0109: Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects. ClinicalTrials.gov NCT01815736

GS-US-292-0111: Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults. ClinicalTrials.gov NCT01797445

GSK 201147: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen. ClinicalTrials.gov NCT02131025

PRO 140 2103: A Phase 2a, Randomized, Study of PRO 140 by Subcutaneous Injection in Adult Subjects with Human Immunodeficiency Virus Type 1 Infection PRO 140 2103

**Lectures:**

---

‘*Global HIV Epidemiology*’, Global Health Seminar, Stanford Center for Innovation in Global Health, September 10, 2014.

**Medical License and Board Certification:**

---

Infectious Diseases, American Board of Internal Medicine 10/2014  
American Board of Internal Medicine 8/2011  
California State Medical License